- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04741646
IJzercitraat en chronische nierziekte bij kinderen (FIT4KID)
Fosfaatbindertherapie en chronische nierziekte bij kinderen
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20 core clinical sites.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
We will conduct a double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20 core clinical sites.
Schedule of Intervention: During the 12-month trial, participants will be given a daily fixed weight-based dose of FC.
Schedule for data collection/analyses to be performed:
Blood for primary outcome assessments will be collected at screening, baseline and at months 3, 6, 9, 12. Blood for safety assessments will be collected at the the months 1, 2, 3, 6, 9, 12.
The primary analyses for this 2-arm trial will compare log-transformed iFGF23 values over 12 months between the treatment and the placebo arms. The analysis will use a linear mixed-effects model, including stratification factors CKD stage and urine protein to creatinine ratio, with random participant effects accounting for repeated measurements, and a fixed treatment effect, which interacts with a time indicator (Months 3-12 vs. Baseline/Screening).
Primary objectives:
- To assess the effects of therapy with FC on iFGF23 levels
- To determine safety and tolerability of FC.
Secondary objectives:
• To assess the effects of FC on anemia and indices of mineral and bone metabolism.
Primary Endpoint:
• iFGF23 level
Safety and Tolerability Endpoints:
• Ability to safely tolerate FC
Secondary Endpoints:
- Anemia
- Indices of mineral and bone metabolism
This is a Phase 2 study with participation from 20 sites that will take 36 months to complete enrollment and a total of 48 months to complete data collection with each participant being part of the study for 12 months.
Study website: fit4kid.dgsom.ucla.edu
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4H4
- BC Children's Hospital Research Institute
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1E8
- SickKids
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- University of California, Los Angeles
-
Orange, California, Verenigde Staten, 92868
- Children's Hospital of Orange County
-
San Francisco, California, Verenigde Staten, 94143
- University of California, San Francisco
-
-
Florida
-
Orlando, Florida, Verenigde Staten, 32806
- Arnold Palmer Hospital for Children
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Indiana U
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64110
- Children's Mercy Hospital, Kansas City
-
St Louis, Missouri, Verenigde Staten, 63130
- Washington U
-
-
New York
-
New York, New York, Verenigde Staten, 11040
- Cohen's Childrens
-
The Bronx, New York, Verenigde Staten, 10467
- Children's Hospital at Montefiore
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27708
- Duke
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, Verenigde Staten, 43205
- Nationwide Children's
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- OHSU
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- Children's Medical Center, Dallas
-
Houston, Texas, Verenigde Staten, 77030
- Baylor College of Medicine
-
Houston, Texas, Verenigde Staten, 77030
- UTH
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Ages 6 to 18 years (inclusive);
- Estimated Glomerular Filtration Rate (GFR) of 15-59 ml/min per 1.73 m2 by modified Chronic Kidney disease in Children (CKiD) under 25 (U25) formula;56
- Serum phosphate <=5.9 mg/dl;
- Serum ferritin <500 ng/ml and TSAT <50%;
- For those patients treated with growth hormone, calcitriol, nutritional vitamin D, iron, and/or erythropoiesis-stimulating agents (ESAs) such treatments must have stable dosing for at least 2 weeks prior to screening;
- Able to swallow tablets;
- Able to eat at least two meals a day;
- In the opinion of the investigator, willing and able to follow the study treatment regimen and comply with the site investigator's recommendations.
Exclusion Criteria:
- Patients currently treated with phosphate binders.
- History of allergy to all ingredients (including non-medical ingredients) in both products (i.e. investigational product and placebo)
- Current intestinal malabsorption, documented in the medical record; disease, inflammatory bowel syndrome, and/or Crohn's Disease.
- Anticipated initiation of dialysis or kidney transplantation within 6 months
- Current or planned future systemic immunosuppressive therapy
- Prior solid organ transplantation
- Receipt of bone marrow transplant within two years of screening
- Current pregnancy, lactation or female subjects who have reached menarche, unless using highly-effective contraception as outlined in section 7.1.1 of Protocol
- Patients participating in other interventional study (observational study participation permitted)
- Poor adherence to medical treatments in the opinion of the investigator
- Cystinosis
- Fanconi syndrome
- Hemochromatosis or laboratory tests indicating possible hemochromatosis or other iron overload (primary or secondary) syndrome
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment Arm
During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals. |
Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
Andere namen:
|
|
Placebo-vergelijker: Control Arm
During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals. |
Placebo to match Ferric Citrate tablets |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
iFGF23 levels
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will lower iFGF23 levels |
12 months
|
|
Safety of Ferric Citrate
Tijdsspanne: 12 months
|
Comparing proportion of subjects with AE and SAE between arms |
12 months
|
|
Tolerability of Ferric Citrate
Tijdsspanne: 12 months
|
Compared with placebo, active treatment will be tolerable |
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Effects on Transferrin Saturation (TSAT)
Tijdsspanne: 12 months
|
Compared with placebo, active treatment with FC will be associated with larger increase in hemoglobin, higher TSAT and higher Ferritin from baseline |
12 months
|
|
Effects on PTH and 1,25 D
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with a larger decrease in PTH and larger increase in 1,25 D from baseline |
12 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
GFR
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with smaller decrease in GFR over time |
12 months
|
|
Osteoid thickness
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with a larger decrease of osteoid thickness from baseline |
12 months
|
|
Effects on bone expression
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with a greater reduction in bone expression of FGF23 |
12 months
|
|
Effects on phosphate
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with a greater reduction in 24 hours urinary phosphate and fractional excertion of phosphate |
12 months
|
|
Effects on calcium
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with a greater incresae in serum calcium levels from baseline |
12 months
|
|
Effects on 1,25 (OH) D levels
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with a greater increase from baseline in serum 1,25 (OH) D levels |
12 months
|
|
Effects on bone biomarkers
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with greater reduction from baseline of bone biomarkers of turnover |
12 months
|
|
Effects on Klotho
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with greater increase from baseline in levels of Klotho |
12 months
|
|
Effects on cFGF23
Tijdsspanne: 12 months
|
Compared to placebo, active treatment with FC will be associated with greater reduction from baseline in cFGF23 |
12 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Isidro B Salusky, MD, University of California, Los Angeles
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Pathologische processen
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Chronische ziekte
- Ziekte attributen
- Nierinsufficiëntie
- Pathologische aandoeningen, tekenen en symptomen
- Nierinsufficiëntie, chronisch
- ijzersterkte
Andere studie-ID-nummers
- U01DK122013 (Subsidie/contract van de Amerikaanse NIH)
- 1U01DK122013 (Subsidie/contract van de Amerikaanse NIH)
- 22-001133 (Andere identificatie: UCLA IRB)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All de-identified clinical data, including study outcomes and participant characteristics will be submitted to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository at the completion of the study. De-identified research samples blood and urine will also be provided to the NIDDK central reporsitory
IPD-tijdsbestek voor delen
the IPD will become available 12 months after study completion.
IPD-toegangscriteria voor delen
Access will be provided by National Institute of Health and any researcher will be able to request access from NIH once the data becomes available.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- ANALYTIC_CODE
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .